Masahiro Hirakawa

Initial dose of fruquintinib and clinical outcomes in patients with refractory metastatic colorectal cancer: a multicenter real-world study

Fruquintinib is an established treatment for patients with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. However, treatment-related adverse events such as hypertension, hand-foot syndrome, and proteinuria frequently require dose modification or...